本帖最后由 老马 于 2013-3-13 13:43 编辑 . I; J, t' u$ o# p3 a0 U: e# S
% f/ {8 J3 Q- ]
健择(吉西他滨)+顺铂+阿瓦斯汀
; Q6 X0 H$ m/ g6 X6 _ Gemzar +Cisplatin + Avastin& D% }- P5 }! P" _4 x7 T; N. ?# F
http://annonc.oxfordjournals.org/content/21/9/1804.full+ P. T* u% J8 {
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
& E: V5 u" h* n; }5 q% \Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
6 G5 z7 \/ \+ rResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
/ R( F" p1 b8 x) p
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 835)
- Q: Q) p# n0 w9 D. g$ n; C9 }
华为网盘附件:
& _9 ~! i4 A' a【华为网盘】ava.JPG
- i) l$ O* Y* u9 y4 M( l+ x" } |